Apogenix’ Partner CANbridge Announces 67 % Five-Year Overall Survival Rate Compared to 8.2 % in Institutional Database With Asunercept Plus Standard of Care in Newly Diagnosed Glioblastoma Multiforme Patients
83% overall survival at two years vs. 34.3% OS from institutional database
17.95 months median progression-free survival vs.5.8months PFS in historical group
Data was presented at the ESMO Sarcoma and Rare Cancers Annual Congress
Full press release:
230327_PR_Apogenix_CANbridge_data
.pdf
Download PDF • 788KB